The introduction of several new therapies for the treatment of multiple sclerosis (MS) has improved the situation of many MS patients. However, the spectrum of potential side effects in MS treatment has also become broader with the introduction of the new therapeutics. Thus, innovative and, in the meantime, well-established laboratory parameters have been introduced for routine testing to improve efficacy and side effects, and therefore the quality of immune treatment regimens. We provide an overview on important aspects of MS treatment and pathogenesis. We then present therapy-specific laboratory parameters of the most important disease-modifying substances. Some have only recently been established and they also have the potential to be in disarray, leading to confusion and insufficient results. Appropriate use of the presented biomarkers is therefore essential and will improve safety in the handling of MS-specific substances.
Find related publications in this database (Keywords)biomarker